Aurobindo Pharma Q1 Review - Pricing Pressure Drags Profitability: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Aurobindo Pharma Ltd. delivered a miss on Q1 FY22 earnings, led by increases in pricing pressure in the U.S. generics segment and reduced offtake of antiretroviral medicines.
It has recently allocated ~$160 million for forward integrating/enhancing product offerings in the Veterinary space and adding abbreviated new drug applications in the U.S. generics segment.
We reduce our FY22E/FY23E earnings per share estimate by 5%/6% to factor in higher competition in U.S. generics and lower other income to account for the usage of capital for acquisitions.
Aurobindo Pharma is working on building a complex product pipeline. However, timely approval remains critical for a better growth outlook over the next two to three years.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.